Longeveron says ELPIS II Phase 2b trial of laromestrocel in HLHS misses primary endpoint at 12 months
Bitget2026/09/23 20:02- Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome.
- The study missed its main efficacy goal, raising uncertainty over the program’s near-term regulatory path.
- Safety remained consistent with prior experience, supporting continued analysis of secondary signals that could shape next steps.
- Management plans to take the full dataset to the FDA to assess options for continuing development in HLHS.
- Separately, the company launched a strategic review, citing cost controls and a focus on funding opportunities in longevity and aging-related frailty.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
